CBRE vs FDMT · P/E 43, rev $35.77B vs rev $37.0K
CBRE Group Inc Class A (CBRE) versus 4D Molecular Therapeutics Inc (FDMT) — a side-by-side from cached financials, not a winner call.
CBRE Group Inc Class A (CBRE) is a real estate services company listed on US.
4D Molecular Therapeutics Inc (FDMT) is a biotechnology company listed on US.
Latest reported CBRE revenue for 2024-12-31 was $35.77B. Net income was $1.04B. Revenue was up 12.0% from 2023-12-31 to 2024-12-31. CBRE currently screens at market cap $41.66B and trailing P/E 42.7.
Latest reported FDMT revenue for 2024-12-31 was $37.0K. Net income was -$160.9M. Revenue was down 99.8% from 2023-12-31 to 2024-12-31. FDMT currently screens at market cap $518.1M.
CBRE currently screens at market cap $41.66B and trailing P/E 42.7. FDMT currently screens at market cap $518.1M.
Not investment advice. Open the CBRE and FDMT stock pages for the full models.
Not investment advice.